electroCore’s Truvaga™ Plus Named “Best Relaxation Gadget” in Esq

ROCKAWAY, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medication and wellness firm, immediately introduced that its Truvaga™ Plus handheld vagus nerve stimulation (nVNS) machine has been named the “Best Relaxation Gadget” in Esquire’s 2025 Sleep Awards.

The annual Sleep Awards from Esquire acknowledge the best and revolutionary options for enhancing relaxation and restoration. Truvaga Plus was chosen by the journal’s editors after in depth hands-on testing, incomes recognition for its skill to calm the nervous system, scale back stress, and promote restorative sleep in simply two-minute periods.

“We are honored to be recognized in Esquire’s Sleep Awards,” mentioned Kelly Benning, Senior Vice President of Truvaga at electroCore. “This recognition is a powerful validation for Truvaga Plus. Sleep is one of the most universal health challenges people face, and having an independent editorial team highlight our device builds confidence for consumers seeking a proven, drug-free way to relax, recharge, and sleep better.”

About electroCore, Inc.

electroCore, Inc. is a business stage bioelectronic expertise firm whose mission is to enhance well being and high quality of life by revolutionary non-invasive bioelectronic applied sciences. The Company’s two main prescription merchandise, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, deal with persistent ache syndromes by non-invasive neuromodulation expertise. Additionally, the corporate commercializes its handheld, and private use Truvaga and TAC-STIM nVNS merchandise using bioelectronic applied sciences to advertise common wellness and human efficiency.

For extra info, go to www.electrocore.com.

About Truvaga Plus

Truvaga Plus is a revolutionary handheld vagus nerve stimulator that makes use of the corporate’s confirmed expertise to rapidly and gently activate the vagus nerve. It’s designed to work with the physique to stability the nervous system to really feel calmer, suppose clearer, and sleep higher. Truvaga Plus is meant for common well being and wellness functions solely and isn’t supposed to diagnose, treatment, mitigate, deal with, or forestall any illness.

• Backed by 20+ years of analysis in bioelectronic medication
• Made within the USA and Shipped from the USA
• Drug-free and non-invasive expertise for stress reduction and sleep
• Quick two-minute periods that match simply into day by day routines
• 30-Day risk-free trial out there at www.truvaga.com

Truvaga Plus stands out as one of many few client wellness units that leverages vagus nerve stimulation science, providing a pure different to medicines and dietary supplements for leisure and sleep.

For extra info on Truvaga Plus, or to buy straight, go to www.truvaga.com.

Forward-Looking Statements

This press launch and different written and oral statements made by representatives of electroCore could comprise forward-looking statements inside the that means of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements embody, however should not restricted to, statements concerning the anticipated outcomes from being Named “Best Relaxation Gadget” in Esquire’s 2025 Sleep Awards, the advantages of Truvaga Plus, the Company’s future enterprise methods, progress alternatives, prospects, product improvement, and market growth, and different statements that aren’t historic in nature, significantly those who make the most of terminology akin to “anticipates,” “will,” “expects,” “believes,” “intends,” and different phrases of comparable that means, derivations of such phrases and the usage of future dates. Actual outcomes might differ from these projected in any forward-looking statements as a result of quite a few components. Such components embody, amongst others, the power to make use of strategic partnerships to offer extra accessibility to these trying to buy our client units, the inherent uncertainties related to growing new merchandise or applied sciences, the power to commercialize its merchandise, electroCore’s outcomes of operations and monetary efficiency, inflation and foreign money fluctuations, and any expectations electroCore could have with respect thereto, competitors within the trade by which electroCore operates and general financial and market situations. Any forward-looking statements are made as of the date of this press launch, and electroCore assumes no obligation to replace the forward-looking statements or to replace the explanation why precise outcomes might differ from these projected within the forward-looking statements, besides as required by legislation. Investors ought to seek the advice of the entire info set forth herein and must also consult with the danger issue disclosure set forth within the stories and different paperwork electroCore recordsdata with the SEC out there at www.sec.gov.

Contact:

ECOR Investor Relations
(973) 302-9253
[email protected]

ECOR Media Relations
(973) 435-8354
[email protected]